article thumbnail

Magazine-How delays derailed Covid-19 vaccination in Africa

Pharmaceutical Technology

The post Magazine-How delays derailed Covid-19 vaccination in Africa appeared first on Pharmaceutical Technology. Read the latest issue of Pharma Technology Focus for all this and more news, insights, data and analysis from the pharmaceutical industry. You can also subscribe here to receive email notifications when a new issue is available.

Vaccines 110
article thumbnail

Magazine: CRISPR gene therapies cut through in 2023

Pharmaceutical Technology

The post Magazine: CRISPR gene therapies cut through in 2023 appeared first on Pharmaceutical Technology. Read the latest issue of Pharma Technology Focus for all this and more news, insights, and analysis from the pharmaceutical industry. You can also subscribe here to receive email notifications when a new issue is available.

FDA 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Magazine: What Rishi Sunak can do for the UK pharma industry

Pharmaceutical Technology

The post Magazine: What Rishi Sunak can do for the UK pharma industry appeared first on Pharmaceutical Technology. All this, and the latest pharma industry news , comment, data, and analysis from GlobalData. Click here to view the latest issue of Pharmaceutical Technology Focus.

93
article thumbnail

Chasing that ‘Time magazine cover potential’

PharmaVoice

Rami Elghandour was already retired. Then CAR-T specialist Arcellx lured him back into the industry to try to change the world.

98
article thumbnail

Magazine: Pharma’s path to Net Zero: Targeting Scope 3 emissions

Pharmaceutical Technology

In this issue: Pharma’s efforts to curb Scope 3 emissions, understanding European Pharmaceutical legislation, and looking back at the pharma industry’s performance in 2023.

98
article thumbnail

Magazine: Left in limbo: when pharma halts rare disease research

Pharmaceutical Technology

Gene therapy research is expensive. Biotechs invest millions of dollars in early research to develop therapies for conditions that might be rare. But when funds are limited and the market potential is dim, such programs are often abandoned by companies, leaving patients and investigators in a bind.

98
article thumbnail

Magazine: UK’s new Netflix-style funding model for antibiotics goes live

Pharmaceutical Technology

In this issue: UK’s new Netflix-style funding model for antibiotics, the Swiss biotech ecosystem recuperates from financial instability of 2023, how patient advocacy can lead to more successful clinical trials, and more.

96